secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001178913-23-002225
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Therapeutics discloses CFO compensation: $260K salary, 45% bonus, 102,860 ADS options at $1.70
--------------------------------------------------------------------------------

- Annual base salary of $260,000 for new CFO Sigal Fattal, plus customary social benefits.
- Yearly bonus potential of 45% of base salary, based on mutually agreed objectives subject to Compensation Committee approval.
- Grant of options to purchase 102,860 American Depositary Shares at $1.70 per ADS, vesting over 4 years.
- Options accelerate upon a change in control (CIC); exercise period extended to 12 months post-termination (except for Cause).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/0001178913-23-002225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/zk2329883.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-002225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer